Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors.
Giannini G, Milazzo FM, Battistuzzi G, Rosi A, Anastasi AM, Petronzelli F, Albertoni C, Tei L, Leone L, Salvini L, De Santis R. Giannini G, et al. Among authors: anastasi am. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253. doi: 10.1016/j.bmc.2019.05.047. Epub 2019 May 31. Bioorg Med Chem. 2019. PMID: 31208798 Free article.
Improved tumor targeting by combined use of two antitenascin antibodies.
Petronzelli F, Pelliccia A, Anastasi AM, D'Alessio V, Albertoni C, Rosi A, Leoni B, De Angelis C, Paganelli G, Palombo G, Dani M, Carminati P, De Santis R. Petronzelli F, et al. Among authors: anastasi am. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7137s-7145s. doi: 10.1158/1078-0432.CCR-1004-0007. Clin Cancer Res. 2005. PMID: 16203813
Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody.
De Santis R, Albertoni C, Petronzelli F, Campo S, D'Alessio V, Rosi A, Anastasi AM, Lindstedt R, Caroni N, Arseni B, Chiodi P, Verdoliva A, Cassani G, Chinol M, Paganelli G, Carminati P. De Santis R, et al. Among authors: anastasi am. Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2191-6. doi: 10.1158/1078-0432.CCR-05-2526. Clin Cancer Res. 2006. PMID: 16609034
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin.
Petronzelli F, Anastasi AM, Pelliccia A, Santapaola D, Albertoni C, Rosi A, Leoni B, Ferrari LE, Paganelli G, Gramiccioli G, Pesce D, Alfano AM, Stasi MA, De Santis R. Petronzelli F, et al. Among authors: anastasi am. Basic Clin Pharmacol Toxicol. 2011 Sep;109(3):145-55. doi: 10.1111/j.1742-7843.2011.00701.x. Epub 2011 Apr 25. Basic Clin Pharmacol Toxicol. 2011. PMID: 21426491 Free article.
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans.
Petronzelli F, Pelliccia A, Anastasi AM, Lindstedt R, Manganello S, Ferrari LE, Albertoni C, Leoni B, Rosi A, D'Alessio V, Deiana K, Paganelli G, De Santis R. Petronzelli F, et al. Among authors: anastasi am. Cancer Biother Radiopharm. 2010 Oct;25(5):563-70. doi: 10.1089/cbr.2010.0797. Epub 2010 Sep 23. Cancer Biother Radiopharm. 2010. PMID: 20863248
Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab.
De Santis R, Rosi A, Anastasi AM, Chiapparino C, Albertoni C, Leoni B, Pelliccia A, Santapaola D, Carollo V, Marra E, Aurisicchio L, Arseni B, Pacello ML, Palmieri G, Battella S, Petronzelli F, Milazzo FM. De Santis R, et al. Among authors: anastasi am. Oncotarget. 2014 Oct 15;5(19):9239-55. doi: 10.18632/oncotarget.2409. Oncotarget. 2014. PMID: 25238453 Free PMC article.
39 results